Potent Patched1 (PTCH1) nanobody TI23 for the activation of the Hedgehog signaling pathway

Activation of hedgehog signaling pathway can facilitate stem cell proliferation and holds great promise in regenerative medicine for a variety of indications. Researchers at Stanford reported the discovery of a potent nanobody that inhibits the pathway suppressor Patched1 (PTCH1) and demonstrated its efficacy in vitro as well as in vivo (mice). Unlike existing Patched1 inhibitor, this nanobody does not rely on lipid modification for its action. In addition, this antibody and its sequence can be engineered to achieve tissue-specific delivery (i.e. AAV-mediated delivery, antibody conjugate). This has therapeutic value for improved bone healing, taste receptor cell regeneration, alleviation of colitis or other conditions.